Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00413504 · ClinicalTrials.gov registry record · NA
Fondaparinux as Monotherapy for DVT and/or Pulmonary Embolism
A NA study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT00413504 is a NA study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 30 participants.
The verdict
NCT00413504, a NA study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
To determine whether fondaparinux as monotherapy without warfarin is effective and safe for long-term (90 days) treatment of DVT and/or PE, thus gaining new long-term experience and data using fondaparinux.
Interventions
- DRUG Fondaparinux
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-04 |
| Est. Completion | 2007-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00413504
The ClinicalTrials.gov registry entry for NCT00413504 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fondaparinux is the first listed.
NCT00413504 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00413504 about?
NCT00413504 is a clinical study titled "Fondaparinux as Monotherapy for DVT and/or Pulmonary Embolism". To determine whether fondaparinux as monotherapy without warfarin is effective and safe for long-term (90 days) treatment of DVT and/or PE, thus gaining new long-term experience and data using fondaparinux.
What is the current status of trial NCT00413504?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2006-04. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00413504?
The interventions under investigation include: Fondaparinux (DRUG).
Who is sponsoring clinical trial NCT00413504?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.